PT3237397T - Compostos de isoquinolina para o tratamento de hiv - Google Patents
Compostos de isoquinolina para o tratamento de hivInfo
- Publication number
- PT3237397T PT3237397T PT15823844T PT15823844T PT3237397T PT 3237397 T PT3237397 T PT 3237397T PT 15823844 T PT15823844 T PT 15823844T PT 15823844 T PT15823844 T PT 15823844T PT 3237397 T PT3237397 T PT 3237397T
- Authority
- PT
- Portugal
- Prior art keywords
- hiv
- treatment
- isoquinoline compounds
- isoquinoline
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462096769P | 2014-12-24 | 2014-12-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT3237397T true PT3237397T (pt) | 2019-02-08 |
Family
ID=55168341
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT15823844T PT3237397T (pt) | 2014-12-24 | 2015-12-23 | Compostos de isoquinolina para o tratamento de hiv |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US9624195B2 (pt) |
| EP (1) | EP3237397B1 (pt) |
| JP (1) | JP6356919B2 (pt) |
| KR (1) | KR101960624B1 (pt) |
| CN (1) | CN107428693B (pt) |
| AU (1) | AU2015371257B2 (pt) |
| BR (1) | BR112017013440A2 (pt) |
| CA (1) | CA2972017C (pt) |
| EA (1) | EA201791304A1 (pt) |
| ES (1) | ES2705709T3 (pt) |
| HK (2) | HK1244271B (pt) |
| IL (1) | IL253052A0 (pt) |
| MX (1) | MX2017008518A (pt) |
| NZ (1) | NZ733125A (pt) |
| PT (1) | PT3237397T (pt) |
| SG (1) | SG11201705184PA (pt) |
| WO (1) | WO2016105534A1 (pt) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2017008518A (es) | 2014-12-24 | 2017-10-25 | Gilead Sciences Inc | Compuestos de isoquinolina para el tratamiento de virus de inmunodeficiencia humana (vih). |
| TWI770552B (zh) | 2014-12-24 | 2022-07-11 | 美商基利科學股份有限公司 | 喹唑啉化合物 |
| JP6385584B2 (ja) | 2014-12-24 | 2018-09-05 | ギリアード サイエンシーズ， インコーポレイテッド | Ｈｉｖの処置のための縮合ピリミジン化合物 |
| HRP20211456T1 (hr) | 2014-12-26 | 2021-12-24 | Emory University | Protuvirusni derivati n4-hidroksicitidina |
| TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療 |
| TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
| KR102248165B1 (ko) | 2017-12-07 | 2021-05-06 | 에모리 유니버시티 | N4-하이드록시사이티딘 및 유도체 및 이와 관련된 항-바이러스 용도 |
| AU2021237718B2 (en) | 2020-03-20 | 2023-09-21 | Gilead Sciences, Inc. | Prodrugs of 4'-C-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same |
| CN116437958A (zh) | 2020-11-11 | 2023-07-14 | 吉利德科学公司 | 鉴定对采用gp120 CD4结合位点导向的抗体的疗法敏感的HIV患者的方法 |
| EP4440701A1 (en) | 2021-12-03 | 2024-10-09 | Gilead Sciences, Inc. | Therapeutic compounds for hiv virus infection |
| CA3235937A1 (en) | 2021-12-03 | 2023-06-08 | Gilead Sciences, Inc. | Therapeutic compounds for hiv virus infection |
| KR20240117588A (ko) | 2021-12-03 | 2024-08-01 | 길리애드 사이언시즈, 인코포레이티드 | Hiv 바이러스 감염 치료용 화합물 |
| TWI843506B (zh) | 2022-04-06 | 2024-05-21 | 美商基利科學股份有限公司 | 橋聯三環胺甲醯基吡啶酮化合物及其用途 |
| TW202402280A (zh) | 2022-07-01 | 2024-01-16 | 美商基利科學股份有限公司 | 可用於ｈｉｖ病毒感染之疾病預防性或治療性治療的治療性化合物 |
| WO2024044477A1 (en) | 2022-08-26 | 2024-02-29 | Gilead Sciences, Inc. | Dosing and scheduling regimen for broadly neutralizing antibodies |
| US20240226130A1 (en) | 2022-10-04 | 2024-07-11 | Gilead Sciences, Inc. | 4'-thionucleoside analogues and their pharmaceutical use |
Family Cites Families (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ197420A (en) | 1980-07-01 | 1984-04-27 | Ici Australia Ltd | -(quinazolin-(2-or 4-)(oxy,ylthio or amino)phen(oxy or ylthio)alkanoic acid derivatives |
| JPH11209350A (ja) | 1998-01-26 | 1999-08-03 | Eisai Co Ltd | 含窒素複素環誘導体およびその医薬 |
| AU7031500A (en) | 1999-09-23 | 2001-04-24 | Astrazeneca Ab | Therapeutic quinazoline compounds |
| JP2003514901A (ja) | 1999-11-22 | 2003-04-22 | ワーナー−ランバート・カンパニー | キナゾリン類およびシクリン依存性キナーゼ酵素を阻害するためのその使用 |
| GB0002032D0 (en) | 2000-01-28 | 2000-03-22 | Zeneca Ltd | Chemical compounds |
| JP2004505110A (ja) | 2000-08-02 | 2004-02-19 | セルテック アール アンド ディ リミテッド | ３位置換イソキノリン−１−イル誘導体 |
| JP2004509876A (ja) | 2000-09-20 | 2004-04-02 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング | ４−アミノ−キナゾリン |
| GB0217015D0 (en) | 2002-07-23 | 2002-08-28 | Bioacta Ltd | Peptide 4 |
| AU2003255482A1 (en) | 2002-10-02 | 2004-04-23 | Merck Patent Gmbh | Use of 4 amino-quinazolines as anti cancer agents |
| EP1628685B1 (en) | 2003-04-25 | 2010-12-08 | Gilead Sciences, Inc. | Antiviral phosphonate analogs |
| WO2004108711A1 (en) | 2003-06-05 | 2004-12-16 | Astrazeneca Ab | Pyrazinil quinazoline derivatives for use in the treatment of tumours |
| JP2007008816A (ja) | 2003-10-15 | 2007-01-18 | Ube Ind Ltd | 新規イソキノリン誘導体 |
| ME03423B (me) | 2004-07-27 | 2020-01-20 | Gilead Sciences Inc | Fosfonatni analozi jedinjenja hiv inhibitora |
| US20070054916A1 (en) | 2004-10-01 | 2007-03-08 | Amgen Inc. | Aryl nitrogen-containing bicyclic compounds and methods of use |
| MX2007005159A (es) | 2004-10-29 | 2007-06-26 | Tibotec Pharm Ltd | Derivados de pirimidina biciclicos inhibidores del vih. |
| KR20060079121A (ko) | 2004-12-31 | 2006-07-05 | 에스케이케미칼주식회사 | 당뇨 및 비만 치료예방에 유효한 퀴나졸린 유도체 |
| US7816352B2 (en) | 2005-03-10 | 2010-10-19 | The Regents Of The University Of California | Apoptosis inhibitors |
| JP5079500B2 (ja) | 2005-04-28 | 2012-11-21 | 協和発酵キリン株式会社 | ２−アミノキナゾリン誘導体 |
| PT1899322E (pt) | 2005-06-28 | 2009-11-09 | Sanofi Aventis | Derivados de isoquinolina como inibidores de rho-cinase |
| BRPI0613861B8 (pt) | 2005-07-26 | 2021-05-25 | Sanofi Aventis | derivados de isoquinolona piperidinil-substituídos como inibidores de rho-cinase |
| US7989461B2 (en) | 2005-12-23 | 2011-08-02 | Amgen Inc. | Substituted quinazolinamine compounds for the treatment of cancer |
| CN101374815B (zh) * | 2006-01-27 | 2013-07-17 | 菲布罗根有限公司 | 使低氧诱导因子（hif）稳定的氰基异喹啉化合物 |
| TW200808739A (en) | 2006-04-06 | 2008-02-16 | Novartis Vaccines & Diagnostic | Quinazolines for PDK1 inhibition |
| WO2007125405A2 (en) | 2006-05-01 | 2007-11-08 | Pfizer Products Inc. | Substituted 2-amino-fused heterocyclic compounds |
| ATE469144T1 (de) | 2006-07-20 | 2010-06-15 | Amgen Inc | Substituierte pyridonverbindungen und anwendungsverfahren |
| US8027888B2 (en) | 2006-08-31 | 2011-09-27 | Experian Interactive Innovation Center, Llc | Online credit card prescreen systems and methods |
| WO2008050808A1 (fr) | 2006-10-24 | 2008-05-02 | Kyowa Hakko Kirin Co., Ltd. | Dérivé de 2-aminoquinazoline |
| ES2625266T3 (es) | 2006-12-27 | 2017-07-19 | Sanofi | Derivados de isoquinolona sustituidos con cicloalquilamina |
| CN101616909B (zh) | 2006-12-27 | 2013-09-11 | 塞诺菲-安万特股份有限公司 | 作为Rho-激酶抑制剂的被取代的异喹啉和异喹啉酮衍生物 |
| WO2008077553A1 (en) | 2006-12-27 | 2008-07-03 | Sanofi-Aventis | Cycloalkylamine substituted isoquinolone and isoquinolinone derivatives |
| WO2008086462A2 (en) | 2007-01-11 | 2008-07-17 | Wyeth | AMINO-SUBSTITUTED QUINAZOLINE DERIVATIVES AS INHIBITORS OF β-CANTENIN/TCF-4 PATHWAY AND CANCER TREATMENT AGENTS |
| JP2010523529A (ja) | 2007-04-06 | 2010-07-15 | ノバルティス アーゲー | プロテインキナーゼ調節剤としての２，６−ナフチリジン誘導体 |
| WO2008157500A1 (en) | 2007-06-17 | 2008-12-24 | Kalypsys, Inc. | Aminoquinazoline cannabinoid receptor modulators for treatment of disease |
| JP5285709B2 (ja) | 2007-11-16 | 2013-09-11 | ギリアード サイエンシス インコーポレーテッド | ヒト免疫不全ウイルスの複製阻害薬 |
| EP2269993B1 (en) | 2008-04-23 | 2013-02-27 | Kyowa Hakko Kirin Co., Ltd. | 2-aminoquinazoline derivative |
| EP2307400B1 (en) | 2008-05-30 | 2014-04-23 | Amgen, Inc | Inhibitors of pi3 kinase |
| GB0812969D0 (en) | 2008-07-15 | 2008-08-20 | Sentinel Oncology Ltd | Pharmaceutical compounds |
| JP5335082B2 (ja) | 2008-08-15 | 2013-11-06 | ビーエーエスエフ ソシエタス・ヨーロピア | ナノスケールの有機固体粒子の製造方法 |
| ES2623794T3 (es) | 2008-12-09 | 2017-07-12 | Gilead Sciences, Inc. | Intermedios para la preparación de moduladores de receptores tipo toll |
| EP2381943A1 (en) | 2008-12-29 | 2011-11-02 | Fovea Pharmaceuticals | Substituted quinazoline compounds |
| US8338441B2 (en) | 2009-05-15 | 2012-12-25 | Gilead Sciences, Inc. | Inhibitors of human immunodeficiency virus replication |
| WO2011035416A1 (en) | 2009-09-25 | 2011-03-31 | Aegera Therapeutics Inc. | Hsp90 modulating compounds, compositions, methods and uses |
| US20130165489A1 (en) | 2010-05-03 | 2013-06-27 | The Trustees Of The University Of Pennsylvania | Small Molecule Modulators of HIV-1 Capsid Stability and Methods Thereof |
| TW201210597A (en) | 2010-06-09 | 2012-03-16 | Gilead Sciences Inc | Inhibitors of hepatitis C virus |
| TW201204723A (en) | 2010-06-22 | 2012-02-01 | Fovea Pharmaceuticals | Heterocyclic compounds, their preparation and their therapeutic application |
| CA2803890A1 (en) | 2010-06-25 | 2011-12-29 | Rutgers, The State University Of New Jersey | Antimicrobial agents |
| MX2012015097A (es) | 2010-07-02 | 2013-05-28 | Gilead Sciences Inc | Derivados de acido naft-2-ilacetico para tratar sida. |
| TWI458711B (zh) | 2010-07-02 | 2014-11-01 | Gilead Sciences Inc | 治療性化合物 |
| WO2012044090A2 (ko) | 2010-09-29 | 2012-04-05 | 크리스탈지노믹스(주) | 단백질 키나제 억제 활성을 갖는 신규한 아미노퀴나졸린 화합물 |
| KR20120038060A (ko) | 2010-10-13 | 2012-04-23 | 롬엔드하스전자재료코리아유한회사 | 신규한 유기 전자재료용 화합물 및 이를 포함하는 유기 전계 발광 소자 |
| AR084280A1 (es) | 2010-12-17 | 2013-05-02 | Hoffmann La Roche | Compuestos heterociclicos nitrogenados sustituidos fusionados en posicion 6,6 y usos de los mismos |
| JP5808826B2 (ja) | 2011-02-23 | 2015-11-10 | インテリカイン， エルエルシー | 複素環化合物およびその使用 |
| MX2013012266A (es) | 2011-04-21 | 2013-11-22 | Gilead Sciences Inc | Compuestos de benzotiazol y su uso farmaceutico. |
| US9540343B2 (en) | 2011-07-06 | 2017-01-10 | Gilead Sciences, Inc. | Compounds for the treatment of HIV |
| CN102863512B (zh) | 2011-07-07 | 2016-04-20 | 上海泓博智源医药技术有限公司 | 抗病毒化合物 |
| EP2794613B1 (en) | 2011-12-20 | 2017-03-29 | Boehringer Ingelheim International GmbH | Condensed triclyclic compounds as inhibitors of hiv replication |
| SG11201401189WA (en) | 2012-04-20 | 2014-09-26 | Gilead Sciences Inc | Benzothiazol- 6 -yl acetic acid derivatives and their use for treating an hiv infection |
| MX357940B (es) | 2012-12-21 | 2018-07-31 | Gilead Sciences Inc | Compuestos de carbamoilpiridona policiclicos y su uso farmaceutico. |
| US20140221378A1 (en) | 2012-12-27 | 2014-08-07 | Japan Tobacco Inc. | SUBSTITUTED SPIROPYRIDO[1,2-a]PYRAZINE DERIVATIVE AND PHARMACEUTICAL USE OF SAME AS HIV INTEGRASE INHIBITOR |
| EP2769722A1 (en) | 2013-02-22 | 2014-08-27 | Ruprecht-Karls-Universität Heidelberg | Compounds for use in inhibiting HIV capsid assembly |
| EP2769723A1 (en) | 2013-02-22 | 2014-08-27 | Ruprecht-Karls-Universität Heidelberg | Compounds for use in inhibiting HIV capsid assembly |
| US9914709B2 (en) * | 2013-06-21 | 2018-03-13 | Yale University | Compositions and methods of treating HIV-1 infections using same |
| MX2017008518A (es) | 2014-12-24 | 2017-10-25 | Gilead Sciences Inc | Compuestos de isoquinolina para el tratamiento de virus de inmunodeficiencia humana (vih). |
| TWI770552B (zh) | 2014-12-24 | 2022-07-11 | 美商基利科學股份有限公司 | 喹唑啉化合物 |
| JP6385584B2 (ja) | 2014-12-24 | 2018-09-05 | ギリアード サイエンシーズ， インコーポレイテッド | Ｈｉｖの処置のための縮合ピリミジン化合物 |
-
2015
- 2015-12-23 MX MX2017008518A patent/MX2017008518A/es unknown
- 2015-12-23 SG SG11201705184PA patent/SG11201705184PA/en unknown
- 2015-12-23 NZ NZ733125A patent/NZ733125A/en not_active IP Right Cessation
- 2015-12-23 CN CN201580075766.9A patent/CN107428693B/zh active Active
- 2015-12-23 EP EP15823844.4A patent/EP3237397B1/en active Active
- 2015-12-23 WO PCT/US2015/000310 patent/WO2016105534A1/en active Application Filing
- 2015-12-23 AU AU2015371257A patent/AU2015371257B2/en active Active
- 2015-12-23 PT PT15823844T patent/PT3237397T/pt unknown
- 2015-12-23 KR KR1020177020463A patent/KR101960624B1/ko active IP Right Grant
- 2015-12-23 US US14/998,131 patent/US9624195B2/en active Active
- 2015-12-23 JP JP2017534246A patent/JP6356919B2/ja active Active
- 2015-12-23 CA CA2972017A patent/CA2972017C/en active Active
- 2015-12-23 BR BR112017013440-3A patent/BR112017013440A2/pt not_active Application Discontinuation
- 2015-12-23 EA EA201791304A patent/EA201791304A1/ru unknown
- 2015-12-23 ES ES15823844T patent/ES2705709T3/es active Active
-
2017
- 2017-06-21 IL IL253052A patent/IL253052A0/en unknown
-
2018
- 2018-03-16 HK HK18103630.0A patent/HK1244271B/zh unknown
- 2018-05-09 HK HK18106002.3A patent/HK1246776A1/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HK1244271B (zh) | 2019-11-29 |
| KR20170096049A (ko) | 2017-08-23 |
| CN107428693B (zh) | 2020-05-29 |
| EP3237397A1 (en) | 2017-11-01 |
| EA201791304A1 (ru) | 2017-12-29 |
| JP6356919B2 (ja) | 2018-07-11 |
| MX2017008518A (es) | 2017-10-25 |
| SG11201705184PA (en) | 2017-07-28 |
| IL253052A0 (en) | 2017-08-31 |
| CA2972017A1 (en) | 2016-06-30 |
| KR101960624B1 (ko) | 2019-03-20 |
| AU2015371257A1 (en) | 2017-07-13 |
| WO2016105534A1 (en) | 2016-06-30 |
| AU2015371257B2 (en) | 2018-09-06 |
| EP3237397B1 (en) | 2018-11-21 |
| US20160237062A1 (en) | 2016-08-18 |
| US9624195B2 (en) | 2017-04-18 |
| CN107428693A (zh) | 2017-12-01 |
| CA2972017C (en) | 2019-06-11 |
| ES2705709T3 (es) | 2019-03-26 |
| HK1246776A1 (zh) | 2018-09-14 |
| NZ733125A (en) | 2018-06-29 |
| JP2018500356A (ja) | 2018-01-11 |
| BR112017013440A2 (pt) | 2018-01-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1246776A1 (zh) | 用於hiv治療的異喹啉化合物 | |
| HRP20181679T1 (hr) | Amidni spojevi za liječenje hiv | |
| HK1244276A1 (zh) | 用於治療hiv的稠合嘧啶化合物 | |
| HK1232147A1 (zh) | 用於治療纖維化的賽尼克韋羅 | |
| HK1258276A1 (zh) | 用於治療hiv的化合物和組合 | |
| ZA201706795B (en) | Process for the preparation of dicycloplatin | |
| HK1244485A1 (zh) | 用於治療神經母細胞瘤的組合物 | |
| HK1257272A1 (zh) | 治療hiv的工具 | |
| IL248267B (en) | A process for preparing converted cycloserines | |
| SG11201702700UA (en) | Methods for the treatment of peri-implantitis | |
| EP3145525A4 (en) | Use of microperoxidases for the treatment of carboxyhemoglobinemia | |
| ZA201608307B (en) | Process for the purification of l-alpha-glycerophosphorylcholine | |
| IL247443B (en) | Process for the preparation of 5-fluorotryptophol | |
| HK1210590A1 (en) | Method for the treatment of hypercholesterolemia | |
| HUP1400518A2 (hu) | Eljárás tofacitinib elõállítására | |
| ZA201704589B (en) | Compounds for the treatment of cancer | |
| AU2014903428A0 (en) | Treatment of HIV |